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INTRODUCTION
Upstream stimulatory factor (USF) is a ubiquitous tran-
scription factor in mammalian cells. It was originally iden-
tified as a cellular transcription factor, which is important
for expression of the adenovirus major late promoter (1, 2).
Two different genes, defined as USF-1 and USF-2, have been
isolated from HeLa cells, and these genes encode 43 and 44
kDa polypeptides, respectively (3-6). These two peptides
have identical DNA-binding specificities and transcription-
al activities (3-6). USF-1 and USF-2 polypeptides are high-
ly divergent in their N-terminal sequences, but they share a
highly conserved C-terminal basic/helix-loop-helix/leucine
zipper (B-HLH-LZ) sequence that is important for the dimer-
ization and DNA-binding of USF (6). Proteins of the B-HLH-
LZ gene family bind to the DNA sequences of the general
type CANNTG, which is referred to as the E-box (7, 8). USF
has been reported to inhibit cellular growth and prolifera-
tion in some cell types (9, 10). We have recently observed
that USF also inhibits the cellular proliferation of rat thyroid
cells, Fischer rat thyroid cell line (FRTL-5) cells, and papillary
thyroid carcinoma cells (11). 
Transforming growth factor-β 1 (TGF-β 1) is a potent, nat-
urally occurring inhibitor of cellular growth and proliferation
(12, 13). The role of TGF-β in tumorigenesis can be suppres-
sive or promoting depending on the developmental stage of
a tumor and its cellular context (14). During an early phase
of tumorigenesis, TGF-βinhibits tumor development and
growth by inducing the arrest of the cell cycle and possibly
apoptosis (14). TGF-β 1 is known to bind to FRTL-5 cells
and inhibit their cellular growth and proliferation (15-18). 
Because both TGF-β 1 and USF suppress FRTL-5 cell pro-
liferation, and because USF increases the activity of TGF-β 1
in some cell types (19), we investigated the effect of USF on
the expression and function of TGF-β 1 in order to clarify the
mechanism of the anti-proliferative effect of USF in FRTL-5
cells. First of all, we assessed whether USF binds to the TGF-
β 1 promoter. Second, we investigated the effect of USF on
the expression of TGF-β 1 and the related cell cycle regula-
tory proteins in FRTL-5 cells. 
870
Keun-Sook Kim*, Hye Seung Jung, 
Yun Jae Chung
1, Tae Sik Jung, 
Hye Won Jang, Myung-Shik Lee, 
Kwang-Won Kim, and Jae Hoon Chung
Division of Endocrinology and Metabolism, 
Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul; 
Samsung Biomedical Research Institute*, Seoul, Korea
1Current affiliation: Division of Endocrinology, 
Department of Internal Medicine, College of Medicine,
Chung-Ang University, Seoul, Korea
Address for correspondence
Jae Hoon Chung, M.D.
Division of Endocrinology and Metabolism, Department
of Medicine, Samsung Medical Center, Sungkyunkwan
University School of Medicine, 50 Irwon-dong, 
Gangnam-gu, Seoul 135-710, Korea 
Tel : +82.2-3410-3434, Fax : +82.2-3410-6956
E-mail : jhchung@smc.samsung.co.kr
*This work was supported by the Samsung Biomedical
Research Institute grant, #SBRI C-A3-226-3, C-A5-
332-1, and C-A6-426-1~2.
J Korean Med Sci 2008; 23: 870-6
ISSN 1011-8934
DOI: 10.3346/jkms.2008.23.5.870
Copyright � The Korean Academy
of Medical Sciences
Overexpression of USF Increases TGF-β β 1 Protein Levels, But G1
Phase Arrest was not Induced in FRTL-5 Cells
Transforming growth factor-β 1 (TGF-β 1) is a potent inhibitor of cellular growth and
proliferation by G1 phase arrest or apoptosis. We investigated the association of
TGF-β 1 with the anti-proliferative effect of upstream stimulatory factor (USF) in Fis-
cher rat thyroid cell line (FRTL-5) cells. [Methyl-
3H] thymidine uptake was measured
after treatment of FRTL-5 cells with TGF-β 1 to identify its anti-proliferative effect.
USF-1 and USF-2 proteins were in vitro translated, and an electrophoretic mobility
shift assay was performed to identify the interaction between USF and the TGF-β 1
promoter. FRTL-5 cells were transfected with USF cDNA, and then the expression
of TGF-β 1 was examined with Northern and Western blotting. The cell cycle-regu-
lating proteins associated with TGF-β 1 were also measured. TGF-β 1 significantly
inhibited [methyl-
3H] thymidine uptake in FRTL-5 cells. Two specific binding sites for
USF were found in the TGF-β 1 promoter: -1,846~-1,841 (CACATG) and -621~-616
(CATGTG). Overexpression of USF increased both the mRNA levels and protein
levels of TGF-β 1. However, the expression of cyclin D1, CDK4, cyclin E, and CDK2,
and the phosphorylation of retinoblastoma protein remained unchanged. Overex-
pression of USF in FRTL-5 cells increased the expression of TGF-β 10 through
specific binding to TGF-β 1 promoter. However, the USF-induced expression of
TGF-β 1 did not cause G1 arrest. 
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MATERIALS AND METHODS
Maintenance of FRTL-5 cells  
Fresh F1 subclone of FRTL-5 cells (Interthyr Research
Foundation, Baltimore, MD, U.S.A.) was grown in a 37℃,
5% CO2-95% O2 incubator with 6H medium that consist-
ed of Coon’s modified Ham’s F-12 (Sigma Chemical, St.
Louis, MO, U.S.A.) supplemented with 5% calf serum, 1
mM nonessential amino acids, 2 mM glutamine, and a mix-
ture of 6 hormones: bovine thyroid stimulating hormone
(TSH) (10 mU/mL), insulin (10 μ g/mL), hydrocortisone
(0.4 ng/mL), transferrin (5 μ g/mL), glycyl-L-histidyl-L-lysine
acetate (2-10 ng/mL), and somatostatin (10 ng/mL). The
culture media were replaced with fresh medium every 3 days,
and the cells were passaged every 7-10 days. In some experi-
ments, the cells were maintained in 5H medium without
TSH for an additional 5-6 days after 70-80% cell conflu-
ence was achieved in the 6H medium.
[Methyl-
3H] thymidine uptake assay after TGF-β 1 treatment
in the FRTL-5 cells
FRTL-5 cells were maintained in 5H medium after being
grown in 6H medium, and they were incubated with 5 ng/
mL of TGF-β 1 (Calbiochem of EMD Biosciences, Inc, Darm-
stadt, Germany) in a 37℃, 5% CO2 humidified incubator
for 36 hr. 
Two or three uCi/well of [methyl-3H] thymidine (Perkin-
Elmer, Wellesley, MA, U.S.A.) was added, and then the cells
were incubated in an incubator maintained at 37℃ for an
additional 6 hr. The cells were washed twice with cold phos-
phate buffered saline (PBS), and were then incubated with 1
mL of 5% trichloroacetic acid for 20 min at room tempera-
ture. The cells were incubated again with 1 mL of 0.5 N
KOH overnight after being washed with 5% trichloroacetic
acid and PBS. [Methyl-3H] thymidine uptake was measured
using a multi-purpose scintillation counter (Beckman Coul-
ter Inc., Fullerton, CA, U.S.A.), and this was expressed as
counts per minute (cpm).
Construction of cDNAs and cloning of the USFs
Total RNA was extracted from the FRTL-5 cells using an
RNA extraction kit (Invitrogen, Carlsbad, CA, U.S.A.), and
the amount of total RNA was measured using a spectropho-
tometer (Pharmacia, Buckinghamshire, England). Two micro-
grams of extracted RNA mixed with 0.1% diethyl pyrocar-
bonate (DEPC)-treated distilled water were incubated for 5
min at 70℃. The cDNA was synthesized by incubation for
60 min at 42℃ using a commercial kit (AccuPower RT
PreMix, BiONEER, Daejeon, Korea). Polymerase chain
reaction (PCR) was performed in a 20 μ L reaction mixture
containing 5 μ L of denatured cDNA, 250 μ M of dNTP
mix, 2.5 U of Taq DNA polymerase (BiONEER), 20 mM
of Tris-HCl (pH 8.8), 10 mM of KCl, 2 mM of MgSO4,
and 0.5 μ M of each primer (the primer sequences are listed
in Table 1). PCR was carried out in a thermal cycler Gene-
Amp 9600 PCR apparatus (Perkin-Elmer Corp., Norwalk,
CT, U.S.A.) according to the following protocol: initial denat-
uration at 95℃ for 5 min, followed by 30 cycles of denatu-
ration at 94 to 95℃ for 30 sec to 1 min, annealing at 52 to
60℃ for 30 sec to 1 min, and extension at 72℃ for 1 to 2
min, and completed by a final extension step at 72℃ for 10
min. Ten microliters of PCR product were analyzed by elec-
trophoresis in 1.5% agarose gel. The PCR products were
purified using a purification kit (PCRquick-spin PCR Prod-
uct Purification Kit, iNtRON Biotechnology, Seongnam,
Korea), and were then cloned into the pcDNA3.1 vectors
using a pcDNA3.1/V5-His TOPO TA expression kit (Invit-
rogen). The cDNA was extracted from a cloned vector using
a QIAprep Spin Miniprep kit (QIAGEN Inc, Valencia, CA,
U.S.A.). Gene sequencing was performed using an automated
direct sequencing analyzer (ABI PRISM, 377 DNA sequencer,
Perkin Elmer, Foster City, CA, U.S.A.).
In vitro translation of USF protein
In vitro translated proteins were made from USF-1 and
USF-2 cDNAs that were cloned into the pcDNA3.1 vec-
tors using a TNT T7 Quick Coupled Transcription/Transla-
tion System (Promega, Madison, WI, U.S.A.). The amount
of synthetic protein was calculated using a commercial kit
assay (Bio-Rad, Hercules, CA, U.S.A.), and was confirmed
by Western blotting and then used for the electrophoretic
mobility shift assay (EMSA). 
EMSA
Four types of E-boxes exist in the rat TGF-β 1 promoter
(E1-E4, Table 2). The sense and antisense strand oligonu-
cleotides that contained each of the E-box sequences were
annealed, and the 5′ end was labeled with [γ -32P]ATP by
using T4 polynucleotide kinase (Promega). The upper-strand
*, Primer sequence of mouse.
USF, upsteam stimulatory factor; TGF-β 1, transforming growth factor-β 1;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
USF-1 F 5′ -ATGAAGGGGCAGCAGAAAAC-3′
R5 ′ -GTTGCTGTCATTCTTGATG-3′
USF-2* F 5′ -ATGGACATGCTGGACCCGGG-3′
R5 ′ -CTGCCGGGTACTCTCGCCC-3′
TGF-β 1F5 ′ -GGCGGACTACTACGCCAAAGAAG-3′
R5 ′ -GACGTCAAAAGACAGCCACTCAG-3′
GAPDH F 5′ -CTGGTGCTGAGTATGTCGTGGA-3′
R5 ′ -GATACATTGGGGGTAGGAACACG-3′
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sequences of the double-stranded oligonucleotides were used
as probes (T1-T4), and they are shown in Table 2.
The EMSA reaction mixtures included 10 μ g of synthetic
protein and reaction buffer (10 mM HEPES; pH 7.9, 60 mM
NaCl, 1 mM EDTA, 2 mM dithiothreitol, 1 μ g poly (dIdC)
and 7% glycerol). After incubation for 10 min at room tem-
perature, 300,000 cpm of radiolabeled probe was added, and
the reaction was allowed to proceed for an additional 45 min.
The reaction mixture was electrophoresed on a 6% poly-
acrylamide gel at 300 V for 2 hr using tris-borate-EDTA
buffer. The gel was dried and exposed to radiography film
overnight at -70℃. Specificity of binding was ascertained
by competition with a 160-fold molar excess of unlabeled
oligonucleotides and by conducting supershift experiments.
For the supershift assay, 2 μ L (0.2 μ g/μ L) of anti-USF-1 or
anti-USF-2 antibody (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, U.S.A.) was preincubated for 2 hr on ice before
the addition of the probes. 
Transfection of cloned cDNA into FRTL-5 cells 
FuGENE6 (Roche Diagnostics, Mannheim, Germany) was
used to transfect DNA plasmids into FRTL-5 cells. FRTL-5
cells were plated onto 6 cm culture dishes, and were grown
to 50-60% confluence in 6H medium and then transferred
to 0.2% calf serum with 4H medium (excluding TSH and
insulin) for 3 days. Eighteen hours prior to transfection, the
medium was changed to 6H medium. Cells were then cotrans-
fected with the pcDNA3 vector (5 μ g) or the USF-expres-
sion vector (5 μ g) plus an expression vector that coded for
green fluorescent protein (5 μ g, pEGFP; Clontech, Sydney,
Australia). The cells were harvested 30 or 50 hr after trans-
fection with FuGene6. The average transfection efficiency into
the FRTL-5 cells was 15% to 30%.
RNA isolation and Northern blot analysis
Total RNA was isolated from FRTL-5 cells that were trans-
fected with an empty vector or the USF-expression vector
using a commercial kit (QIAGEN Inc). Five micrograms of
total RNA were run on a denatured 1% agarose gel (final
formaldehyde concentration: 2.2 M); they were transferred
to a positively-charged nylon membrane (Roche) and immo-
bilized by UV cross-linking. Full-length rat USF-1, mouse
USF-2, rat TGF-β 1, and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) cDNAs were used as probes and were
synthesized using a commercial kit (PCR DIG Probe Synthe-
sis Kit, Roche). Hybridization was carried out overnight at
50℃with 50 ng of cDNA probe in DIG Easy Hyb (Roche).
Subsequent washing and detection with CSPD (Roche) were
carried out as recommended by the protocol of the manu-
facturer. Each experiment was conducted twice. The degree
of RNA expression was expressed as values that were adjust-
ed by those of GAPDH.
Western blot analysis
To obtain the total cellular proteins, FRTL-5 cells trans-
fected with empty PCDNA3.1 vector or with the USF-expres-
sion vector were resuspended in RIPA buffer (50 mM tris-Cl;
pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid
and 0.1% SDS) supplemented with NaF, Na3VO4, phenyl-
methylsulfonyl fluoride (PMSF), and complete protease
inhibitor cocktail tablets (Roche) after the cells had been
washed with cold PBS. The cell suspension was incubated
on ice for 10 min and then centrifuged at 15,000×g for 20
min at 4℃. The resultant supernatant contained the total
cellular protein. The amount of cellular protein was calcu-
lated using a commercial kit assay (Bio-Rad, Hercules, CA,
U.S.A.). For the Western immunoblots, 20 μ g of protein was
analyzed on SDS-PAGE, transferred to nitrocellulose mem-
branes (Amersham, Germany), blocked in 5% skim milk,
incubated with primary antibodies overnight at 4℃, and
then revealed by treatment with SuperSignal
� West Femto
Maximum Sensitivity Substrate (Pierce, Rockford, IL, U.S.A.).
Antibody to retinoblastoma protein (Rb) used for Western
blot analysis was purchased from BD Pharmingen (San Diego,
CA, U.S.A.), and the other antibodies were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, U.S.A.).
Statistical significance
All of the experiments were repeated at least three times
with different batches of cells. The data for thymidine uptake
E-box name E-box sequences E-box locus Oligomer name Oligomer sequences*
E1 CAAGTG -1,610~-1,605 T1 5′ -GGGGGTCAAGTGGCAGAGGA
E2 CACATG -1,846~-1,841 T2 5′ -CTAGCATCACATGGCCCCAT
E2’ CACATG -3,514~-3,509 T2’ 5′ -CACACTCCCACATGCTGAGAT
E3 CATGTG -621~-616 T3 5′ -ATGGCTTTTGCCATGTGCCTAGCAGCCCA
E3’ CATGTG -1,563~-1,558 T3’ 5′ -CTAGAACTCATGTGTAGCCCA
E4 CAGGTG -678~-673 T4 5′ -ACCCTTCCAGGTGAGGTCTT
Table 2. E-boxes in the rat TGF-β 1 promoter and the oligomer sequences containing each E-box
*, E-boxes in each oligomer sequences are in bold print and the discriminating sequences are underlined.
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of FRTL-5 cells were analyzed using the SPSS-PC software
program (version 11.0, Chicago, IL, U.S.A.). The values of
thymidine uptake were analyzed using the Student’s t-test,
and were expressed as mean±standard deviation. p values
less than 0.05 were considered significant. 
RESULTS
Effect of TGF-β 1 on the cellular growth in FRTL-5 cells
Treatment with 5 ng/mL of TGF-β 1 significantly decreased
[methyl-3H]-thymidine uptake by 60-70% in FRTL-5 cells
(Fig. 1). 
Binding of USF to the specific loci of the TGF-β 1 promoter
USF-1 and USF-2 proteins were in vitro translated and then
confirmed by Western blotting (right upper box of Fig. 2).
To identify binding of USF-1 and USF-2 proteins to the
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Fig. 1. Inhibition of cellular proliferation by TGF-β 1 in FRTL-5 cells. 
FRTL-5 cells were cultured with 5 ng/mL of TGF-β 1, and thymi-
dine uptake of the cells was measured. The values of thymidine
uptake were analyzed using Student’s t-test, and were expressed
as mean±standard deviation. Treatment with TGF-β 1 significant-
ly decreased thymidine uptake by 60-70% in FRTL-5 cells. 
*p<0.05 vs. no TGF-β 1 treatment.
Fig. 2. Electrophoretic mobility shift assay (EMSA) of the complexes between the USF protein and the E-box sequences in the TGF-β 1
promoter. The in vitro translated USF-1 and USF-2 were confirmed by Western blotting, and this is illustrated in a box located in the right
upper side of the figure. Four types of E-boxes (E1-E4) existed in the TGF-β 1 promoter, and each was tested to determine whether they
would bind to USF-1 and USF-2 by using EMSA (black arrows). Among them, the affinities to E2 and E3 were much stronger than the
affinities shown to E1 and E4. Cold competitors eliminated the DNA-protein complexes, and a specific anti-USF-1 or anti-USF-2 antibody
shifted these complexes to an upper position to cause ‘super-shifts’ (white arrows). 
Competitor
E1
USF-1 USF-2
E1 5’-CAAGTG
E2 5’-CACATG
E3 5’-CATGTG
E4 5’-CAGGTG
- + -- + -- + --+ -
Anti-USF-1 -- + --+ --+ -- +
E2 E3 E4
Competitor
E1
- + -- + -- + -- + -
Anti-USF-2 -- + --+ --+ -- +
E2 E3 E4 Western blot
USF-1 USF-2
Fig. 3. Electrophoretic mobility shift assay (EMSA) of the complexes between USF and the E2/E3 of the different loci in the TGF-β 1 promoter.
There were two loci of CACATG (E2) and CATGTG (E3), respectively: -1,846~-1,841 (E2) and -3,514~-3,509 (E2’), and -621~-616 (E3)
and -1,563~-1,558 (E3’). Specific sites for USF binding were identified by performing EMSA with four probes (T2, T2’, T3, and T3’) that con-
tained each E-box. The specific sites were revealed as -1,846~-1,841 and -621~-616. Black arrows indicate the DNA-protein complex-
es, and the white arrows indicate their super-shifts according to the specific antibodies.
Competitor
T2
USF-1
T2 5’-CACATG (-1,846~-1,841)
T2’ 5’-CACATG (-3,514~-3,509)
T3 5’-CATGTG (-621~-616)
T3’ 5’-CATGTG (-1,563~-1,558)
- + --+ -- + -- + -
Anti-USF-1 --+ --+ -- + -- +
T2’ T3 T3’
Competitor
T2
USF-2
- + -- + -- + -- + -
Anti-USF-2 -- + --+ --+ -- +
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TGF-β 1 promoter, we observed the DNA-protein complex
between four different E-box sequences of the rat TGF-β 1
promoter (T1, T2, T3, and T4 in Table 2) and the USF pro-
teins by performing EMSA (as indicated by the black arrows
in Fig. 2). Among them, the affinities for binding to T2 and
T3 were much stronger. Cold competitors eliminated the
DNA-protein complexes, and a specific anti-USF-1 or anti-
USF-2 antibody shifted these complexes to an upper posi-
tion to make ‘super-shifts’ (as indicated by the white arrows
in Fig. 2). Two loci of E2 (5′ -CACATG) and E3 (5′ -CAT-
GTG) were detected in the rat TGF-β 1 promoter, respec-
tively: -1,846~-1,841 (E2), -3,514~-3,509 (E2’), and -621~
-616 (E3), -1,563~-1,558 (E3’). The specific sites for USF
binding were evaluated by performing EMSA with four
probes (T2, T2’, T3, and T3’) that contained each E-box,
and were identified as -1,846~-1,841 (E2) and -621~-616
(E3) (Fig. 3). 
Effect of USF overexpression on the expression of TGF-
β 1 and its related proteins in FRTL-5 cells
Transient transfection with USF-1 and USF-2 induced
their overexpression in FRTL-5 cells. Overexpression of USF-
1 and USF-2 increased both the mRNA levels and protein
levels of TGF-β 1 in FRTL-5 cells (Fig. 4). 
The expression of G1 phase-related proteins, including
cyclin D1, CDK4, cyclin E, and CDK2, remained unchanged
by USF overexpression, although the levels of p27, a cell cycle
inhibitor, were increased. In addition, the overexpression of
USF-1 and USF-2 did not alter the levels of phosphoryla-
tion of Rb protein in FRTL-5 cells (Fig. 5).
DISCUSSION
USF has been reported to inhibit cellular growth and pro-
liferation in some cell types (9, 10). We have recently observed
that both USF-1 and USF-2 play a role in suppressing the
cellular proliferation of normal thyrocytes and thyroid pap-
illary carcinoma cells, while they maintained the TSH-stim-
ulated production of cAMP (11). However, the exact mech-
anism of the anti-proliferative effect of USF overexpression
was not identified. TGF-β 1 is a potent, naturally occurring
inhibitor of cell growth (13), it has a high affinity for FRTL-
5 cells, and it inhibits their cellular growth (15-18); there-
fore, this study examined the role of TGF-β 1 in FRTL-5 cells
overexpressing USF. 
Inhibition of cellular growth by TGF-β 1 has been observed
in normal feline thyroid cells, human thyroid cells, and the
human papillary thyroid carcinoma cell line (17, 20). First
of all, we confirmed that TGF-β 1 significantly decreased
the uptake of [methyl-3H]-thymidine in FRTL-5 cells. There-
fore, we conducted a study on the relationship between USF
and TGF-β 1. There have been a few reports on this relation-
ship thus far: USF-1 and USF-2 are known to bind to the
TGF-β 1 promoter and increase its activity in mesangial cells,
glioblastoma, embryonal carcinoma, breast carcinoma, and
choriocarcinoma cells (19, 21, 22). However, the effect of
USF on the expression of TGF-β 1 in thyrocytes has not yet
been reported. USF binds to DNA as a homodimer or het-
erodimer at a specific site that is characterized by an E-box
(5′ -CANNTG) (3, 5, 9). In this study, we demonstrated that
USF-1 and USF-2 proteins strongly bound to the specific
sequences (CACATG in -1,846 to -1,841 and CATGTG in
-621 to -616) of the TGF-β 1 promoter, and the overexpres-
sion of USF increased the mRNA and protein levels of TGF-
Fig. 4. Effects of USF-1 and USF-2 overexpression on the expres-
sion of TGF-β 1 in the FRTL-5 cells. Total RNA and protein were
isolated from FRTL-5 cells that were transiently overexpressed with
USF. Northern (left panel) and Western blotting (right panel) were
performed to evaluate the mRNA and protein levels of USF and
TGF-β 1. Expression of TGF-β 1 was induced by the overexpres-
sion of USF-1 and USF-2. Three sets of experiments were repeat-
ed. GAPDH was used as the internal control for Northern blotting,
and tubulin was used as the internal control for Western blotting.
Fig. 5. Effects of USF-1 and USF-2 overexpression on the expres-
sion of TGF-β 1-related proteins in FRTL-5 cells. Total protein was
isolated from FRTL-5 cells that transiently overexpressed USF,
and Western blotting was then performed. The p27 levels were
increased by USF overexpression, but the cyclin D1, CDK4, cyclin
E, and CDK2 levels were not changed. Accordingly, dephospho-
rylation of retinoblastoma (Rb) protein was not observed. Three
sets of experiments were performed, and tubulin was used as
the internal control.
ppRb, hyperphosphorylated Rb; pRb, hypophosphorylated Rb.
USF-1
Northern blot
12 3 12 3 12 3
Western blot
USF-2
TGF-β β 1
GAPDH
Lane1, pcDNA3.1; Lane 2, USF-1; Lane 3, USF-2
Lane 1, pcDNA3.1; 
Lane 2, USF-1; 
Lane 3, USF-2
USF-1
Western blot
USF-1
USF-2
P27
Cyclin D1
CDK4
Cyclin E
CDK2
Rb
Tubulin
USF-2
TGF-β β 1
Tubulin
ppRb
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β 1 in FRTL-5 cells. Other E-boxes such as E1 and E4 in Fig.
2 were very week in their affinity to USF, which suggests that
there are other factors than nucleotide sequences determining
the binding of USF at E-box. It is apparent in the Fig. 3 because
even E-boxes having the same sequences in the TGF-β 1 pro-
moter showed different affinity to USF. Taking into consider-
ation the anti-proliferative effect of TGF-β 1, these findings
suggested that USF might inhibit cell proliferation through
the induction of TGF-β 1 after binding to its promoter. 
As commented on earlier, TGF-βregulates cellular growth
and proliferation in a cell-specific manner. In most epithe-
lial cells, TGF-βis a potent inhibitor of cellular growth and
proliferation; it arrests the cell cycle in the G1 phase by mod-
ulating the cell cycle regulators, especially the CDK inhibitors,
CDK4, CDK2, cyclin D, and cyclin E, and by eventually
dephosphorylating Rb protein (23). TGF-βinduces the expres-
sion of CDK inhibitors such as p15, p21, and p27 (24). They,
in turn, downregulate CDK4 and G1/S phosphatase CDC25A
(25, 26), and they decrease the expression of c-Myc, which
again down-regulates p15 (27). Inactivation of the CDK-
cyclin complexes contributes to dephosphorylation of Rb
protein (28). Rb protein is a primary target of the action of
TGF-β 1, and as Rb dephosphorylation induces G1 phase
arrest (29), the main anti-proliferative mechanism of TGF-
β 1 on the thyroid cells has been reported as G1 phase arrest
(16, 18). However, we were not able to observe G1 arrest in
the USF-overexpressing FRTL-5 cells, although the expres-
sion of TGF-β 1 was increased. We did not evaluate the mech-
anism for it, but overexpression of USF might influence the
activity of G1 phase-related cyclin modulators and the phos-
phorylation status of Rb protein. Instead, we observed G2/M
phase arrest (11). The G2/M phase arrest was accompanied
by the modification of the expression of the G2/M-related
regulators such as cyclin B1 and CDK1 (11). The effect of
TGF-β 1 on the progression of the G2/M phase is not yet
clear. We observed the increase of p27 which could contribute
to the G2/M phase arrest. Hashimoto et al. recently report-
ed that TGF-β 1 induced the cell cycle arrest not at G1 phase
but at G2 phase in some hepatoma cells, which was thought
to be through the stabilization of Wee1 (30). Although we
did not examine the activity of Wee1, the overexpression of
USF might affect Wee1 activity and induce G2/M arrest.
However, we cannot exclude the possibility that the role of
TGF-β 1 in the USF-regulated anti-proliferative effects on
FRTL-5 cells is very limited, regardless of the binding activ-
ities of USFs to TGF-β 1 promoter. 
In conclusion, we demonstrated that TGF-β 1 decreased
the proliferation of FRTL-5 cells. We also observed that over-
expression of USF-1 and USF-2 increased the expression of
TGF-β 1 in FRTL-5 cells after specifically binding to the
TGF-β 1 promoter. However, dephosphorylation of Rb was
not induced, and this was concordant with the finding that
cell cycle arrest was observed at the G2/M phase, and was
not seen at the G1 phase (11). The mechanism related to
the reason that USF-induced TGF-β 1 expression did not
cause dephoshorylation of Rb protein will be evaluated and
reported on in the future.
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